We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
Allogene Therapeutics’ Post
More Relevant Posts
-
During a recent ALL Hub Steering Committee meeting, André Baruchel, led an insightful debate on the number of circulating blasts required to move to apheresis for a patient with R/R ALL, as part of a wider discussion of “Key considerations when preparing patients with ALL for CAR T-cell therapy.” Watch the full video here: https://loom.ly/NH9Rgfo #ALL #ALLsm #leusm
To view or add a comment, sign in
-
Hybrid AF™ Therapy has proven to be over 2 times more effective at halting atrial arrhythmias compared to endocardial ablation alone. Don't settle for less when it comes to your long-standing persistent Afib patients. Explore more benefits of Hybrid AF Therapy today: https://okt.to/yNMEhu #HybridAFTherapy #Epeeps #Cardiac
To view or add a comment, sign in
-
-
Off the heels of the successful completion of our MICRO1 and MICRO(T) trials, MICRO2 is a pivotal, FDA-facing study intended to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction (CMD). Today, the vast majority of these patients - most of whom are women and likely do not know their symptoms are due to CMD - are either misdiagnosed or almost entirely ignored under the current standard of care, despite the fact that research has consistently demonstrated CMD's significant impact on both a patient's quality of life AND their long-term prognosis. MICRO2 will compare CardioFlux MCG's diagnostic performance against the current industry gold standard of invasively measured Coronary Flow Reserve, and if successful, could represent evidence of the first zero-contact, zero-radiation diagnostic option for patients suffering from this condition. Our team expects to ramp patient enrollment across the next several weeks and anticipates a first read-out of results in Q1 of 2025. Congratulations to both our team at Genetesis and our incredible clinical partners on the first of what are hopefully many MICRO2 milestones! #microvascular #CMD #INOCA #CardioFluxMCG #MICRO2
To view or add a comment, sign in
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks.
To view or add a comment, sign in
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/d95Rs78p
To view or add a comment, sign in
-
-
CroiValve yesterday presented favourable 6-month data from the TANDEM I first-in-human study of its novel Duo transcatheter tricuspid coaptation valve system for treating tricuspid regurgitation. The unique Duo system works in tandem with the native valve using a novel anchoring approach across the annulus. Key results showed: 📉 Significant TR reduction in ≥85% of patients 🚀 Improved quality of life 💯 100% survival, no arrhythmias/pacing issues 🎯 Successful device positioning/remodeling ⏱️ With a 43 minute average procedure time, the Duo system demonstrates early promise for treating tricuspid valve disease. 💪 CroiValve will continue evaluating this innovative therapy through additional clinical studies. #TTVR #MedTech #structuralheart #medicaldevices
To view or add a comment, sign in
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/e84Zj_7E
To view or add a comment, sign in
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gCrkhD8S
To view or add a comment, sign in
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/dfmFNwSD
To view or add a comment, sign in
-
-
Business Development Director at Fortrea (formerly Covance, Labcorp). Supporting clinical development Phase I-IV for biotech companies
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gTg2T2rj
To view or add a comment, sign in
-